← CellScience workspace
Rendered from briefs/cellscience/truth-gate.md

Truth Gate — CellScience (CS-01 astaxanthin softgels)

David's verdicts on the 35 research claims, finalized on the Launch Center 2026-09-01 (ask cs-truth-gate). This file is the only claims source downstream phases may build on. Raw claims: truth-gate-claims.json.

Rule: anything in the BANNED list may not appear in brand identity, PDP copy, ads, email, or creative briefs — in any paraphrase.

Verdict counts: 27 TRUE · 8 FALSE · 0 feedback. All four bold claims (x1–x4) were approved, including x3 against Claude's recommendation — the gate is David's and it rules; where practical, execution still pairs "Harvard-level" language with the actual cited journals.


✅ TRUE — the foundation (27)

Problems (4)

Mechanism (5 — all cleared)

Benefits & proof (6)

Customer icons (3)

Credibility & edge (5)

Bold claims (4 — all approved)


⛔ BANNED — never in any paraphrase (8)


Copy consequences (operative reading)

  1. The Collagen Shield leads — solution-side only. m1/x1/b2 carry the MMP-1 story as protection that holds. The plateau/attack problem narrative (p1/p2) is gone: never tell her collagen failed her — tell her the Shield makes everything she takes hold.
  2. Problem sections build from p3/p5/p6/p7: the Antioxidant Blindspot, joint "cellular rusting," skincare fatigue, and the undiscovered-apex-ingredient angle.
  3. Eyes: benefit-forward. b3/b6/x2 are cleared; the p4 problem dramatization is not.
  4. No glow language (b5) anywhere — the visible-color story lives in photography only.
  5. 12mg appears as a spec, never as an argument (b7 banned).

ROUND 2 — the ClarityMD angles (finalized 2026-09-02, ask cs-truth-gate-r2)

31 TRUE · 3 FALSE · 0 feedback. Raw claims: truth-gate-claims-r2.json. Map: competitor-angles-claritymd.md.

✅ TRUE — additions (29 new + 2 reversals)

⛔ FALSE — round 2 (3)

Standing BANNED after round 2 (6)

p1 collagen-plateau narrative · p2 enzymes-faster-than-you-rebuild · p4 eye-strain problem dramatization · p8 human-capital framing · b8 carrier-oil superiority · c6 bag-as-selling-point. (b5 and b7 unbanned 2026-09-02.)